Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody ...

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...

Flagship Pioneering-founded Generate Biomedicines is tacking on a gigantic $273 million in series C funds, though the haul didn't reach the heights of the biotech’s previous $370 million raise back in ...

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 billion, ...

Generate Biomedicines is setting out to “program” medicine by almost instantaneously creating models of new proteins. Launched out of life sciences venture firm Flagship Pioneering, it raised a large ...